Purdue University
The researchers believe the chemosensitivity signatures generated with this approach from human and dog samples could be broadly applicable across cancer types.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.